TG Therapeutics, Inc. (NASDAQ:TGTX), today announced the publication of data from a post-hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in treatment-naïve adult patients with relapsing forms of multiple sclerosis (RMS). The article, titled "Disease outcomes with ublituximab in treatment-naïve participants: Subpopulation analyses of the Phase 3 ULTIMATE I and II studies in participants with relapsing multiple sclerosis," authored by Derrick Robertson, MD, of the University of South Florida, Tampa, FL and colleagues, was published in Frontiers in Immunology.

These post-hoc analyses demonstrate that BRIUMVI provided significant and consistent improvements across multiple clinical and MRI endpoints compared to teriflunomide in patients who had not received a prior disease-modifying therapy, including those treated early in their disease course.